SEC Form 4 · accession 0001193125-26-388909
Pharvaris N.V. · PHVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Glassman
Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 12:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001830487
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 9, 2026 | M | 8,000 | $20.00 | A | 18,500 | D | |
| Common StockF2 | Sep 9, 2026 | S | 8,000 | $37.5495 | D | 10,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $20.00 | Sep 9, 2026 | M | 8,000 | D | — | Feb 5, 2031 | Common Stock | 8,000 | 0 | D |
Explanation of responses
- F1This is a scheduled exercise and sale from 10b5-1 trading plan.
- F2The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.21 to $37.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F325% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.